A rapid and sensitive method for determination of veliparib (ABT-888), in human plasma, bone marrow cells and supernatant by using LC/MS/MS

A rapid and sensitive method was developed and validated using a liquid chromatographic method with tandem mass spectrometry detection (LC/MS/MS) for determination of veliparib (ABT-888) in plasma, bone marrow supernatant, and bone marrow cells. Sample preparation involved a single protein precipita...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pharmaceutical and biomedical analysis Vol. 52; no. 1; pp. 122 - 128
Main Authors: Reinhardt, Sarah, Zhao, Ming, Mnatsakanyan, Aleksander, Xu, Linping, Ricklis, Rebecca M., Chen, Alice, Karp, Judith E., Rudek, Michelle A.
Format: Journal Article
Language:English
Published: Amsterdam Elsevier B.V 01-05-2010
Elsevier
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A rapid and sensitive method was developed and validated using a liquid chromatographic method with tandem mass spectrometry detection (LC/MS/MS) for determination of veliparib (ABT-888) in plasma, bone marrow supernatant, and bone marrow cells. Sample preparation involved a single protein precipitation step by the addition of the sample with acetonitrile. Separation of veliparib and the internal standard, A620223.69, was achieved on a Atlantis™ dC 18 column (100 mm × 2.1 mm, 3 μm) column using a mobile phase consisting of acetonitrile–ammonium acetate (2 mM) containing formic acid (0.1%, v/v) using isocratic flow at 0.2 mL/min for 3 min. The analyte and internal standard were monitored by tandem mass spectrometry with electrospray positive ionization. Linear calibration curves were generated over the range of 5–1000 nM. The values for both within day and between day precision and accuracy were well within the generally accepted criteria for analytical methods. This method was subsequently used to measure concentrations of veliparib in cancer patients receiving an oral daily dose of 10 mg with demonstration of drug accumulation in the marrow compartment and in the target leukemia bone marrow cells.
ISSN:0731-7085
1873-264X
DOI:10.1016/j.jpba.2009.12.015